Drug intelligence / Profile preview

glidobactin A

Development stage
Preclinical
Lead developer
University of Hawai'i Cancer Center
Modality
Peptides, Small Molecules
Administration
Intravenous
01

Overview

Glidobactin A is a natural product belonging to the syrbactin class of proteasome inhibitors, originally isolated from the bacterium *Polyangium brachysporum*. It is a macrocyclic peptide-like molecule that acts as a potent and irreversible inhibitor of the eukaryotic 20S proteasome. Specifically, it targets the chymotrypsin-like activity of the proteasome by covalently binding to the catalytic N-terminal threonine residues. Preclinical research has demonstrated that glidobactin A induces apoptosis and autophagy in various cancer models, including neuroblastoma, multiple myeloma, and ovarian cancer. Its structural scaffold serves as a platform for the development of novel proteasome inhibitors with potential therapeutic applications in oncology.

Other names
Cepafungin I
02

Targets

PSMB5 (Proteasome subunit beta Type-5)PSMB7 (Proteasome subunit beta type-7)PSMB6 (Proteasome 20S subunit beta 6)

Beyond the preview

Go deeper on glidobactin A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on glidobactin A.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call